HALO

Halozyme Therapeutics, Inc.

Healthcare · $13.1B market cap

Share price

$109.86

close of Oct 3, 2026

Fair value

$66.59

Sticker Price

Payback Price

$26.63

buy price

Overpriced

HALO is Overpriced: at $109.86 it trades 65% above its fair value of $66.59. Its buy price (Payback Price) is $26.63, 76% below today's price. Business quality is strong: all 5 key numbers clear the 10% bar.

How we valued it

Buffett Normalized. A profitable, growing business, so we project its earnings 10 years ahead and work out what that is worth today.

Business quality

5 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth26.3% a year✓

Equity per share growth10.1% a year✓

Sales growth28.5% a year✓

Free cash flow growth25.5% a year✓

Return on invested capital21.1%✓

Follow HALO

Get notified when it reaches its buy price of $26.63. Free.

Create a free account

Superinvestors

2 of the investors we track hold HALO. Who we track

Torray Funds

Torray Funds · as of Q2 2026

$3.0M

38,703 shares

Richard Pzena

Pzena Investment Management · as of Q2 2026

$317K

4,049 shares

Insider activity

Since Jun 12, 2026: no open-market purchases, 24 sales worth $13.7M and 18 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Torley Helen

PRESIDENT AND CEO · 2026-09-11

Sold

$485K

Torley Helen

PRESIDENT AND CEO · 2026-09-11

Sold

$1.7M

Torley Helen

PRESIDENT AND CEO · 2026-09-10

Sold

$582K

Torley Helen

PRESIDENT AND CEO · 2026-09-10

Sold

$1.6M

Torley Helen

PRESIDENT AND CEO · 2026-09-09

Sold

$11K

Show all 24 sales

Torley Helen

PRESIDENT AND CEO · 2026-09-09

Sold

$711K

Torley Helen

PRESIDENT AND CEO · 2026-09-09

Sold

$1.4M

Torley Helen

PRESIDENT AND CEO · 2026-08-19

Sold

$345K

Torley Helen

PRESIDENT AND CEO · 2026-08-19

Sold

$1.0M

Torley Helen

PRESIDENT AND CEO · 2026-08-19

Sold

$766K

Torley Helen

PRESIDENT AND CEO · 2026-08-18

Sold

$986K

Torley Helen

PRESIDENT AND CEO · 2026-08-18

Sold

$510K

Torley Helen

PRESIDENT AND CEO · 2026-08-18

Sold

$588K

Torley Helen

PRESIDENT AND CEO · 2026-08-17

Sold

$776K

Torley Helen

PRESIDENT AND CEO · 2026-08-17

Sold

$923K

Torley Helen

PRESIDENT AND CEO · 2026-08-17

Sold

$214K

Torley Helen

PRESIDENT AND CEO · 2026-08-17

Sold

$50K

Torley Helen

PRESIDENT AND CEO · 2026-08-17

Sold

$89K

Connaughton Bernadette

director · 2026-08-10

Sold

$167K

Torley Helen

PRESIDENT AND CEO · 2026-07-08

Sold

$83K

Torley Helen

PRESIDENT AND CEO · 2026-07-08

Sold

$70K

Connaughton Bernadette

director · 2026-07-01

Sold

$48K

Connaughton Bernadette

director · 2026-07-01

Sold

$76K

Krishnan Mahesh

director · 2026-06-29

Sold

$548K

Other filings

Torley Helen

PRESIDENT AND CEO · 2026-09-11

Option exercise

$368K

Torley Helen

PRESIDENT AND CEO · 2026-09-10

Option exercise

$368K

Torley Helen

PRESIDENT AND CEO · 2026-09-09

Option exercise

$368K

Appelhans Dannielle

director · 2026-09-01

Award

$192K

Appelhans Dannielle

director · 2026-09-01

Award

1,161 shares

Show all 18 other filings

Torley Helen

PRESIDENT AND CEO · 2026-08-19

Option exercise

$368K

Torley Helen

PRESIDENT AND CEO · 2026-08-18

Option exercise

$368K

Torley Helen

PRESIDENT AND CEO · 2026-08-17

Option exercise

$368K

Torley Helen

PRESIDENT AND CEO · 2026-07-08

Option exercise

$23K

Snellgrove Darren

SVP, Chief Financial Officer · 2026-07-01

Award

41,554 shares

Snellgrove Darren

SVP, Chief Financial Officer · 2026-07-01

Award

$9.8M

RAMSAY DAVID A

EVP, PRESIDENT, DRUG DELIVERY · 2026-07-01

Award

16,232 shares

RAMSAY DAVID A

EVP, PRESIDENT, DRUG DELIVERY · 2026-07-01

Award

$3.1M

RAMSAY DAVID A

EVP, PRESIDENT, DRUG DELIVERY · 2026-06-30

Tax withholding

$423K

RAMSAY DAVID A

EVP, PRESIDENT, DRUG DELIVERY · 2026-06-30

Option exercise

10,000 shares

Krishnan Mahesh

director · 2026-06-29

Option exercise

$281K

Snyder Mark Howard

SVP, CHIEF LEGAL OFFICER · 2026-06-12

Tax withholding

$189K

Snyder Mark Howard

SVP, CHIEF LEGAL OFFICER · 2026-06-12

Option exercise

5,034 shares

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works

Verdict

How we valued it

Business quality

Superinvestors

Insider activity

Sales

Other filings

About Halozyme Therapeutics, Inc.